Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Total Liabilities (2020 - 2025)

Insight Molecular Diagnostics' Total Liabilities history spans 6 years, with the latest figure at $53.1 million for Q3 2025.

  • For Q3 2025, Total Liabilities fell 12.18% year-over-year to $53.1 million; the TTM value through Sep 2025 reached $53.1 million, down 12.18%, while the annual FY2024 figure was $47.4 million, 3.94% down from the prior year.
  • Total Liabilities for Q3 2025 was $53.1 million at Insight Molecular Diagnostics, up from $49.4 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $94.3 million in Q4 2021 and bottomed at $22.7 million in Q1 2021.
  • The 5-year median for Total Liabilities is $53.1 million (2025), against an average of $58.0 million.
  • The largest annual shift saw Total Liabilities skyrocketed 330.1% in 2021 before it plummeted 55.95% in 2023.
  • A 5-year view of Total Liabilities shows it stood at $94.3 million in 2021, then crashed by 35.88% to $60.5 million in 2022, then fell by 18.51% to $49.3 million in 2023, then fell by 3.94% to $47.4 million in 2024, then increased by 12.2% to $53.1 million in 2025.
  • Per Business Quant, the three most recent readings for IMDX's Total Liabilities are $53.1 million (Q3 2025), $49.4 million (Q2 2025), and $50.1 million (Q1 2025).